PSC
HZNP

Piper Sandler & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Piper Sandler & Co’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-10,000
Closed -$198K – 94
2015
Q3 		$198K Buy
+10,000
New +$316K 0.21% 68
2014
Q3 		– Sell
-25,000
Closed -$396K – 182
2014
Q2 		$396K Buy
+25,000
New +$357K 0.29% 29

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Piper Sandler & Co's HZNP Position: Q4 2015 in Review

Piper Sandler & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2015, closing a stake of 10,000 shares — an estimated $198K sold.

Piper Sandler & Co first reported a position in HZNP in Q2 2014 and held it in 2 quarters. The position peaked at $396K in Q2 2014. 202 funds tracked by Wall St. Rank hold HZNP as of Q4 2015.

  • Piper Sandler & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 10,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2015, an estimated $198K.
  • Piper Sandler & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and held it in 2 quarters.
  • Piper Sandler & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $396K in Q2 2014.
  • 202 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2015.

Based on Piper Sandler & Co's 13F filing for Q4 2015, filed 16 Feb 2016.